Novo Nordisk

Page 7 of 9

WHO
Health

A billion people worldwide are obese and Ozempic and other weight-loss drugs aren’t a solution, WHO says

By Naomi Kresge, Angela Feliciano and Bloomberg
March 1, 2024
BOXES OF WEGOVY DRUGS
Lifestyle

Novo Nordisk faces competition close to home as Danish rival Zealand Pharma’s shares jump 35% on ‘groundbreaking’ weight-loss drug trial results

By
February 27, 2024
Minnesotans can buy insulin for just $35 a month over the next 5 years under a state settlement with Eli Lilly
Health

Minnesotans can buy insulin for just $35 a month over the next 5 years under a state settlement with Eli Lilly

By Steve Karnowski and The Associated Press
February 8, 2024
Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
Retail

Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge

By
February 8, 2024
European stocks are giving off a ’90s vibe, Morgan Stanley says, and it could set them on a path to 16% returns in 2024
Finance

European stocks are giving off a ’90s vibe, Morgan Stanley says, and it could set them on a path to 16% returns in 2024

By
February 6, 2024
Lars Fruergaard Jorgensen holding flashcards and talking
Retail

Novo Nordisk CEO says he was ‘surprised’ to see the popularity of weight-loss drugs in Europe—and people’s readiness to pay out of pocket for them

By
February 5, 2024
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
Retail

Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year

By
January 31, 2024
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
Health

North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030

By Simone Foxman, Madison Muller and Bloomberg
January 27, 2024
Ozempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’
Health

Ozempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’

By Ellie Harmsworth and Bloomberg
December 24, 2023
Ozempic manufactured by Novo Nordisk packaging on December 7, 2023.
Health

Novo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival

By Christian Wienberg and Bloomberg
December 13, 2023
Roche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
Finance

Roche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot

By Paula Doenecke and Bloomberg
December 4, 2023
Weight loss drugs are all the rage.
Health

Pfizer rocked by failure of weight-loss pill set to compete with lucrative rivals Ozempic and Mounjaro

By Madison Muller and Bloomberg
December 1, 2023
Lars Fruergaard Jorgensen holding a microphone in one hand and paper flashcards in the other hand
Health

Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs

By
November 27, 2023
Novo Nordisk responds to U.S. rival Eli Lilly by announcing new $2.3 billion investment in France to keep up with soaring demand for weight-loss drugs
Health

Novo Nordisk responds to U.S. rival Eli Lilly by announcing new $2.3 billion investment in France to keep up with soaring demand for weight-loss drugs

By
November 23, 2023
Obesity drugs in Ozempic, Wegovy and Mounjaro are trimming back the Thanksgiving ‘food orgy’
Health

Obesity drugs in Ozempic, Wegovy and Mounjaro are trimming back the Thanksgiving ‘food orgy’

By Jonel Aleccia and The Associated Press
November 20, 2023

Most Popular